25th August, 2026

(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th floor
Plot no. C/1, G Block
Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Scrip Symbol: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II
L-1840 Luxembourg

Sub: USFDA inspection at Company's manufacturing facility in Pithampur, India

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our earlier intimations on the captioned subject dated 18th February 2023, 5th August 2023, and 18th November 2023, we hereby notify that the United States Food and Drug Administration ('USFDA') has conducted a follow-up current Good Manufacturing Practices (cGMP) inspection at the Company's manufacturing facility at Pithampur, India from 17th August 2026 to 25th August 2026.

On conclusion of the inspection, the Company received seven (7) inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited
RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.08.25 15:59:36 +05'30'
Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani